⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for spms

Every month we try and update this database with for spms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional StudyNCT04895202
Secondary Progr...
Siponimod
18 Years - Novartis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisNCT01416181
Secondary Progr...
natalizumab
Placebo
18 Years - 58 YearsBiogen
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)NCT04792567
Secondary Progr...
BAF312
Baseline diseas...
BNT162
mRNA-1273
18 Years - 100 YearsNovartis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisNCT01416181
Secondary Progr...
natalizumab
Placebo
18 Years - 58 YearsBiogen
Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple SclerosisNCT02228213
Secondary Progr...
MIS416
Saline
18 Years - 70 YearsInnate Immunotherapeutics
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927
Secondary Progr...
Mayzent
- 99 YearsNovartis
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927
Secondary Progr...
Mayzent
- 99 YearsNovartis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)NCT04792567
Secondary Progr...
BAF312
Baseline diseas...
BNT162
mRNA-1273
18 Years - 100 YearsNovartis
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisNCT02430532
Multiple Sclero...
dimethyl fumara...
Placebo
18 Years - 58 YearsBiogen
Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple SclerosisNCT01647321
Secondary Progr...
Active cycling
Passive cycling
18 Years - 68 YearsJohns Hopkins University
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: